Kagocel® for the Prevention of ARVI and Influenza in Young People
Condition: Acute Upper Respiratory Tract Infection; Influenza; Respiratory Viral Infection
MeSH terms: Infections; Communicable Diseases; Influenza, Human; Respiratory Tract Infections; Virus Diseases
Study type: Observational [Patient Registry]

Summary: 
      This study evaluates the use of Kagocel for the prevention of acute respiratory viral
      infections (ARVI) and influenza during the epidemic rise in the incidence of diseases in
      Russia in 2018 (epidemiology: the number of cases during the period of Kagocel administration
      and follow-up, bacterial exacerbations, the number of repeated episodes (reinfection),
      demographics of patients, safety, adherence to treatment) in students at risk due to stress,
      lack of sleep and fatigue.
    

Detailed description: 
      This non-interventional prospective study included 75 health students over the age of 18 who
      had no symptoms of acute respiratory viral infections (ARVI) and influenza at the time of
      inclusion and had not taken any antiviral medications to prevent ARVI and influenza for 30
      days before.

      The total duration of the study was 2 months: the first month participants took either
      Kagocel (the main group), or did not take anything at all (the control group), during the
      next 1 month all participants were monitored.

      The diagnosis of influenza and ARVI has been confirmed in accordance with the world health
      organization (WHO) guidelines for the pharmacological treatment of pandemic influenza A
      (H1N1) 2009 and other influenza viruses. All patient examinations are conducted in accordance
      with local routine clinical practice and local and international standards of care.

      By the study were analysed and compared those data between groups:

        -  demography

        -  anamnesis data (the incidence of ARVI and flu for previous year, the date of the lastest
           episode of the disease, the presence of concomitant diseases, including ENT-organs, the
           date of the lastest influenza vaccination).

        -  timelines: start of Kagocel's prevention - only for the group receiving Kagocel's
           prevention; start of the disease; duration of ARVI and influenza symptoms (fever,
           headache, runny nose, sore throat, cough); start of treatment

        -  symptomatic therapy (Yes/no, drug name)

        -  bacterial exacerbations (Yes/no)

        -  treatment of bacterial exacerbations (Yes/no)

        -  adverse events
    

Intervention name(s): Kagocel; No one
Intervention type(s): Drug; Drug
Intervention description(s): Investigators could prescribe other drugs in frame of routine clinical practice; Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
Observational model: Cohort
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        The young people over the age of 18 who had no symptoms of acute respiratory viral
        infections (ARVI) and influenza at the time of inclusion and had not taken any antiviral
        medications to prevent ARVI and influenza than 30 days prior to inclusion in this study.
      
Keywords: Influenza; Acute Upper Respiratory Tract Infection; acute respiratory viral infection; ARVI; flu; cold; AURI